Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q4 CY2025 results , with sales up 13.8% year on year to $44.65 million. Its non-GAAP loss of $0.12 per share was 10.8% above ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q3 CY2025, with sales falling 3.8% year on year to $38.44 million. Its non-GAAP loss of $0.12 per share was 14.2% above analysts’ ...

Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...

MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select ...